Database for
Therapeutic Antibodies
Therapeutic Antibodies
| Entry ID | 200 |
| INN | Telisotuzumab adizutecan |
| Status | Clinical |
| Drug code(s) | ABBV-400 |
| Brand name | None |
| mAb sequence source | mAb humanized |
| General Molecular Category | ADC |
| Format, general category | Full length Ab conjugate |
| Format details | None |
| Isotype (Fc) | IgG1 |
| Light chain isotype | kappa |
| Linker | Valine-Alanine |
| Ave. DAR | ___ |
| Conjugated/fused moiety | Topoisomerase I inhibitor |
| Discovery method/technology | None |
| Target(s) | cMET |
| Indications of clinical studies | Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma, Colorectal cancer, Solid tumors, Non-small cell lung cancer |
| Primary therapeutic area | Cancer |
| Most advanced stage of development (global) | Phase 3 |
| Status | Active |
| Start of clinical phase (IND filing or first Phase 1) | September 01, 2021 |
| Start of Phase 2 | |
| Start of Phase 3 | |
| Date BLA/NDA submitted to FDA | |
| Year of first approval (global) | None |
| Date of first US approval | |
| INN, US product name | None |
| US or EU approved indications | None |
| Company | Pierre Fabre |
| Licensee/Partner | AbbVie |
| Comments about company or candidate | NCT06614192 Phase 3 in colorectal cancer due to start in Nov 2024. NCT06107413 Phase 2 in colorectal cancer started in Nov 2023 NCT06084481 Phase 1 in solid tumors due to start in Nov 2023. NCT05029882 is a Phase 1 Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer Receiving Intravenous (IV) ABBV-400 results published (Doi: 10.1200/JCO.2023.41.16_suppl.3015). |
| Full address of company | Paris, France Europe France https://www.pierre-fabre.com/en-us |
ABBV-400 is c-Met ADC that utilizes a topoisomerase inhibitor payload; cMet is also known as hepatocyte growth factor receptor. Antibody described in "A novel antagonist anti-cMet antibody with antitumor activities targeting both ligand-dependent and ligand-independent c-Met receptors" (DOI: 10.1002/ijc.30174)
| Anticipated events | None |
| Factor(s) contributing to discontinuation | None |